Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTX-4430 When Administered Orally to Cystic Fibrosis Patients for Fifteen Days
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Acebilustat (Primary) ; Mannitol
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Celtaxsys
- 03 Nov 2016 According to a Celtaxsys media release the result from this trial published in the second paper of Clinical and Translational Science (CTS), a publication of the American Society for Clinical Pharmacology and Therapeutics (ASCPT).
- 03 Nov 2016 Results published in the Celtaxsys Media Release.
- 28 Oct 2016 According to a Celtaxsys media release the result from this trial will be published in the journal Clinical and Translational Science (CTS), a publication of the American Society for Clinical Pharmacology and Therapeutics (ASCPT).